HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO China Medical System (867 HK) - About the IPO in Singapore and Concerns on Valuation Outlook

China Healthcare Weekly(July20)-WuXi AppTec 25H1, Sino Biopharm Acquire LaNova, United Lab Placement

What Happens to China Healthcare? - The Soaring Shares, the Turning Point, and the Top Picks

Pre-IPO Wuhan Dazhong Dental Medical - Valuation Performance May Disappoint Investors

Pre-IPO Cloudbreak Pharma (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Nanjing Leads Biolabs - The Future Prospects of the Pipeline Are Worth Looking Forward To

Pre-IPO Foshan Haitian Flavouring & Food Company - Thoughts on the IPO Pricing

Pre-IPO Saint Bella (PHIP Updates) - Some Points Worth the Attention

Equity Capital Markets

Nanjing Leads Biolabs / Equity Capital Markets

<ul>
<li>Even if the first indication of LBL-024 is approved, it wouldn't bring significant performance growth due to small market size for EP-NEC. Commercialization prospects of LBL-007 are also not optimistic.</li>
<li>Leads Biolabs’ CD3 pipelines would have higher hope to be successful. However, early-stage investors transferred their equity at a discount before IPO, which may reflect their concerns about the prospects.</li>
<li>Comfortable valuation is RMB3-4bn, which provides investors with a greater margin of safety.Especially in the context of current bull market of innovative drugs, biotech valuation has been full of bubble </li>
</ul>


Even if the first indication of LBL-024 is approved, it wouldn't bring significant performance growth due to small market size for EP-NEC. Commercialization prospects of LBL-007 are also not optimistic.
Leads Biolabs’ CD3 pipelines would have higher hope to be successful. However, early-stage investors transferred their equity at a discount before IPO, which may reflect their concerns about the prospects.
Comfortable valuation is RMB3-4bn, which provides investors with a greater margin of safety.Especially in the context of current bull market of innovative drugs, biotech valuation has been full of bubble 


Pre-IPO Nanjing Leads Biolabs (PHIP Updates) - Thoughts on the Valuation and the Outlook